These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20377874)

  • 1. Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study.
    Pinkawa M; Holy R; Piroth MD; Fischedick K; Schaar S; Székely-Orbán D; Eble MJ
    Radiat Oncol; 2010 Apr; 5():27. PubMed ID: 20377874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life Changes >10 Years After Postoperative Radiation Therapy After Radical Prostatectomy for Prostate Cancer.
    Leufgens F; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):382-388. PubMed ID: 31201895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
    Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Holy R; Krenkel B; Eble MJ
    Radiother Oncol; 2008 Jul; 88(1):135-9. PubMed ID: 18022263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Nussen S; Eble MJ
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):83-9. PubMed ID: 17855010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy.
    Lilleby W; Fosså SD; Waehre HR; Olsen DR
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):735-43. PubMed ID: 10098428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
    Staffurth JN; Haviland JS; Wilkins A; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Birtle A; Malik Z; Panades M; Eswar C; Graham J; Russell M; Ferguson C; O'Sullivan JM; Cruickshank CA; Dearnaley D; Hall E;
    Eur Urol Oncol; 2021 Dec; 4(6):980-992. PubMed ID: 34489210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost.
    Pinkawa M; Piroth MD; Holy R; Klotz J; Djukic V; Corral NE; Caffaro M; Winz OH; Krohn T; Mottaghy FM; Eble MJ
    Radiat Oncol; 2012 Jan; 7():14. PubMed ID: 22289620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer.
    Zelefsky MJ; Poon BY; Eastham J; Vickers A; Pei X; Scardino PT
    Radiother Oncol; 2016 Jan; 118(1):85-91. PubMed ID: 26780999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer.
    Geinitz H; Thamm R; Scholz C; Heinrich C; Prause N; Kerndl S; Keller M; Busch R; Molls M; Zimmermann FB
    Strahlenther Onkol; 2010 Jan; 186(1):46-52. PubMed ID: 20082188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-grade toxicity after conformal radiation therapy for prostate cancer--impact of bladder volume.
    Pinkawa M; Fischedick K; Asadpour B; Gagel B; Piroth MD; Eble MJ
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):835-41. PubMed ID: 16289911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life.
    Seymour ZA; Hamstra DA; Daignault-Newton S; Bosch W; Michalski J; Gay HA; Pinkawa M
    BJU Int; 2020 Sep; 126(3):367-372. PubMed ID: 32333714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.
    Lips I; Dehnad H; Kruger AB; van Moorselaar J; van der Heide U; Battermann J; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):656-61. PubMed ID: 17512127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis.
    Pinkawa M; Piroth MD; Holy R; Escobar-Corral N; Caffaro M; Djukic V; Klotz J; Eble MJ
    Strahlenther Onkol; 2012 Oct; 188(10):917-25. PubMed ID: 22933033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.
    Ferrer M; Guedea F; Suárez JF; de Paula B; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Boladeras A; Ayala A; Craven-Bratle J; Ávila M; Cunillera O; Pardo Y; Alonso J; Aguiló F;
    Radiother Oncol; 2013 Aug; 108(2):306-13. PubMed ID: 23849168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
    Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.
    Lilleby W; Stensvold A; Dahl AA
    Prostate; 2013 Jul; 73(10):1038-47. PubMed ID: 23532709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer.
    Zhang Y; Li P; Yu Q; Wu S; Chen X; Zhang Q; Fu S
    Radiat Oncol; 2019 Jun; 14(1):94. PubMed ID: 31164172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.
    Lilleby W; Stensvold A; Dahl AA
    Acta Oncol; 2014 Oct; 53(10):1380-9. PubMed ID: 24844918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.